Amgen’s $3.7B ChemoCentryx acquisition adds a new piece to autoimmune strategy August 5, 2022 AutoBot Amgen, autoimmune disease, BioPharma, biopharma nl, California, deals, Pharma, Thousand Oaks 0 Amgen’s drug portfolio boasts several biologic drugs that are blockbuster sellers. In acquiring ChemoCentryx for $3.7 billion, the pharmaceutical giant gains a company entirely focused on developing small molecule alternatives to biologic medicines.